This product is freeze dried. All water molecules have been removed.
Every lot is tried & tested in a relevant biological assay.
Gimenez-Gallego, G. et al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 3329.
Alomone Labs Charybdotoxin inhibits KCa1.1 channels heterologously expressed in Xenopus oocytes.A. Example of time course showing reversible effect of 20 nM and 50 nM Charybdotoxin (#STC-325) during 100 sec application on the current amplitude. Membrane holding potential was -100 mV stepped to 0 mV during 200 ms following another step to 80 mV during 600 msec. B. Superimposed example traces of KCa1.1 channel currents in response to ramp depolarization before (Control) and during the application of 20 nM or 50 nM of Charybdotoxin for 100 sec.
Charybdotoxin was originally isolated from the venom of the Israeli scorpion Leiurus quinquestriatus hebraeus1. Charybdotoxin blocks KCa1.1 (large conductance Ca2+-activated K+, Slo) channels in nM concentrations2 as well as KV1.2 (Kd, 14 nM) and KV1.3 (Kd, 2.6 nM) channels3. However, experiments with cloned KCa1.1 channels demonstrate the strong effect of the sloβ subunits on the potency of block by Charybdotoxin (see for example4).
Alomone Labs Charybdotoxin blocks BKCa channels in human chorionic plate arterial smooth muscle cells.Inhibition of BKCa channels with Charybdotoxin (#STC-325) which abolished outward currents at +80 mV. Cells were voltage clamped at -60 mV and step depolarised from -70 mV to +80 mV for 500 ms in 10 mV increments and repolarised to -40 mV.Adapted from Brereton, M.F. et al. (2013) PLoS ONE 8, e57451. with permission of PLoS.
Charybdotoxin (#STC-325) is a highly pure, synthetic, and biologically active peptide toxin.
- Fellerhoff-Losch, B. et al. (2015) J. Neural Transm. 123, 137.
- Lee, J. et al. (2014) Develop. Neurobiol. 74, 1.
- Lopez-Gonzalez, I. et al. (2014) Mol. Hum. Reprod. 20, 619.
- Brereton, M.F. et al. (2013) PLoS ONE 8, e57451.
- Cao, Z. et al. (2013) Nat. Commun. 4, 1.
- Chen, M. et al. (2013) Mol. Neurobiol. 48, 794.
- Gonzalez Corrochano, R. et al. (2013) Br. J. Pharmacol. 169, 449.
- Cosyns, S.M. and Lefebvre, R.A. (2012) Eur. J. Pharmacol. 686, 104.
- Sun, P. et al. (2011) J. Neurosci. 31, 16464.
- Tanner, G.R. et al. (2011) J. Neurosci. 31, 8689.
- Malinina, E. et al. (2010) J. Neurophysiol. 104, 200.
- Sciaccaluga, M. et al. (2010) Am. J. Physiol. 299, C175.
- Dhaese, I. and Lefebvre, R.A. (2009) Eur. J. Pharmacol. 606, 180.
- Begg, M. et al. (2001) J. Physiol. 531, 95.
- Anti-KCNN4 (KCa3.1, SK4) Antibody (#APC-064)
- Mouse Anti-KCNN4 (KCa3.1, SK4) (extracellular) Antibody (#ALM-051)
- Mouse Anti-KCNN4 (KCa3.1, SK4) (extracellular)-Biotin Antibody (#ALM-051-B)
- Anti-KV1.3 (KCNA3) (extracellular) Antibody (#APC-101)
- Anti-KV1.3 (KCNA3) (extracellular)-Biotin Antibody (#APC-101-B)
- Anti-KV1.3 (KCNA3) (extracellular)-PE Antibody (#APC-101-PE)
- Kaliotoxin-1 (#STK-370)
- Spinoxin (#STS-500)
- Urotoxin (#STU-200)